Search
Nautilus Biotechnology Inc
NAUTAdd to Watchlist
2.150USD
-0.140-6.11%
Close 11-05 16:00（ET）
273.85MMarket Cap
LossP/E TTM
After-hours 19:38 (ET)2.080USD-0.120-5.46%
After-hours 19:38 (ET)Nautilus Biotechnology Inc (NAUT) Stock Price Target & Forecast
Analyst Rating
Based on 4 analysts giving stock ratings to Nautilus Biotechnology Inc in the past month.
Strong Buy
2 Strong Buy
2 Buy
0 Hold
0 Sell
0 Strong Sell
Target Price
4.000USD+46.52%
NAUT Analyst Recommendation Trends
In the current month, NAUT has received 2 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. NAUT average Analyst price target in the last month is 4.000.
2026-11
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2
2
1
1
1
1
1
1
2
2
1
1
1
1
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4
4
2
2
2
2
2
2
NAUT Analyst Rating for Peer Comparison
Updated: Nov 5, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
0
0
27
argenx SE
ARGX
10
14
3
0
0
27
Ionis Pharmaceuticals Inc
IONS
6
16
4
0
0
26
Insmed Inc
INSM
6
18
1
0
0
25
Revolution Medicines Inc
RVMD
10
14
1
0
0
25
Kymera Therapeutics Inc
KYMR
9
12
2
0
0
23
CRISPR Therapeutics AG
CRSP
4
8
11
0
0
23
Tempus AI Inc
TEM
4
7
11
0
1
23
IQVIA Holdings Inc
IQV
8
13
1
0
0
22
Biontech SE
BNTX
4
12
6
0
0
22
Financial Forecasting
Based on analysts' estimates, NAUT EPS is projected to reach -0.135 in FY2026Q4, following reported EPS of -0.123 in FY2026Q3. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
FY2027Q1
Forecast
-0.14
-0.14
-0.14
-0.14
-0.13
Actual
-0.12
-0.11
-0.12
--
--
Surprise
+19.96%
+15.70%
+12.22%
--
--
FAQs
What is Nautilus Biotechnology Inc's expected revenue for the next quarter?
Nautilus Biotechnology Inc's expected revenue is 206.25K.
What is Nautilus Biotechnology Inc's price target?
Analysts forecast that Nautilus Biotechnology Inc's price target is USD 4.00, with the highest forecast at USD 4.00 and the lowest forecast at USD 4.00.
How have Nautilus Biotechnology IncNAUT's recent earnings per share performed?
The market expectation was USD -0.12, while Nautilus Biotechnology IncNAUT's earnings per share (EPS) for the previous quarter was USD -0.11. EPS for the next quarter is expected at USD -0.14.
What is the analyst rating for Nautilus Biotechnology Inc?
Based on the ratings of Nautilus Biotechnology Inc's stock from 4 analysts, most analysts support a STRONG BUY trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as STRONG BUY. Please note that this is not trading advice. You still need to conduct your own analysis.